Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes
Author(s) -
Dori Bilik,
Laura N. McEwen,
Morton B. Brown,
Nathan E. Pomeroy,
Catherine Kim,
Keiko Asao,
Jesse C. Crosson,
O. Kenrik Duru,
Assiamira Ferrara,
Victoria C. Hsiao,
Andrew J. Karter,
Pearl Lee,
David G. Marrero,
Joe V. Selby,
Usha Subramanian,
William H. Herman
Publication year - 2010
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2009-2638
Subject(s) - medicine , pioglitazone , rosiglitazone , thiazolidinedione , odds ratio , diabetes mellitus , type 2 diabetes , body mass index , insulin , endocrinology
Thiazolidinedione (TZD) treatment has been associated with fractures. The purpose of this study was to examine the association between TZD treatment and fractures in type 2 diabetic patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom